Portola Pharmaceuticals Inc (PTLA) Shares Bought by JPMorgan Chase & Co.
JPMorgan Chase & Co. increased its holdings in Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 3.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 744,702 shares of the biopharmaceutical company’s stock after purchasing an additional 26,544 shares during the period. JPMorgan Chase & Co. owned 1.29% of Portola Pharmaceuticals worth $40,081,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of PTLA. Renaissance Technologies LLC purchased a new position in Portola Pharmaceuticals in the 2nd quarter worth approximately $21,187,000. Kornitzer Capital Management Inc. KS increased its stake in Portola Pharmaceuticals by 38.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 727,812 shares of the biopharmaceutical company’s stock worth $39,324,000 after acquiring an additional 202,925 shares during the last quarter. Zevenbergen Capital Investments LLC increased its stake in Portola Pharmaceuticals by 71.4% in the 2nd quarter. Zevenbergen Capital Investments LLC now owns 452,190 shares of the biopharmaceutical company’s stock worth $25,400,000 after acquiring an additional 188,320 shares during the last quarter. Blue Jay Capital Management LLC bought a new stake in Portola Pharmaceuticals in the 2nd quarter worth approximately $6,740,000. Finally, State Street Corp increased its stake in Portola Pharmaceuticals by 5.3% in the 2nd quarter. State Street Corp now owns 2,085,838 shares of the biopharmaceutical company’s stock worth $117,164,000 after acquiring an additional 105,207 shares during the last quarter. 87.45% of the stock is currently owned by institutional investors.
A number of research firms have issued reports on PTLA. BidaskClub downgraded Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday. Goldman Sachs Group began coverage on Portola Pharmaceuticals in a research note on Friday, December 1st. They issued a “buy” rating and a $75.00 price objective on the stock. Oppenheimer reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Portola Pharmaceuticals in a research note on Tuesday, November 7th. Morgan Stanley reaffirmed an “overweight” rating and issued a $81.00 price objective (up previously from $75.00) on shares of Portola Pharmaceuticals in a research note on Friday, October 6th. Finally, Credit Suisse Group raised Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 target price on the stock in a research report on Wednesday, August 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $71.15.
Portola Pharmaceuticals Inc (PTLA) opened at $53.02 on Monday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.31 and a current ratio of 8.31. Portola Pharmaceuticals Inc has a 12-month low of $17.74 and a 12-month high of $67.10.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.49) by $0.08. The firm had revenue of $3.83 million for the quarter, compared to the consensus estimate of $4.71 million. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The company’s revenue for the quarter was down 58.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.64) EPS. equities research analysts anticipate that Portola Pharmaceuticals Inc will post -4.95 earnings per share for the current year.
Portola Pharmaceuticals Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Want to see what other hedge funds are holding PTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Portola Pharmaceuticals Inc (NASDAQ:PTLA).
Receive News & Ratings for Portola Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.